Stocks

Why Aurora Cannabis Inc stock is gaining today

By Wealth Awesome Newsroom -
Stocks & ETFs:ACB.TO
Photos provided by Pexels

Aurora Cannabis Inc (ACB.TO) is on the rise, with shares climbing 1.08% in the latest trading session, reflecting strong performance driven by international medical sales.

In the latest trading session, Aurora Cannabis Inc (ACB.TO) saw its stock price increase by 1.08%, closing at CA$4.20. This uptick is attributed to the company’s robust quarterly performance, particularly in its medical cannabis segment, which has shown significant growth in international markets.

Advertisement

Qtrade Direct Investing

Get up to $2,000 cash back

Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.

Aurora Cannabis Inc

ACB.TO

Full stock page →

ACB.TO

Aurora Cannabis Inc

Source:WealthAwesomeWealthAwesome
$1.88 (-32.75%)
120 day period
$3.79$4.94$6.08Jan 20Apr 16Jul 10

Market cap

$237.24M

52W high

$9.33

52W low

$3.74

1W change

-5.62%

Beta

1.35

Analyst Price Targets

Based on analyst covering ACB

📈

Wall Street analysts forecast ACB stock price to rise 51.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$5.84

+51.3% Upside

Current Price

C$3.86

Last close

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on ACB's historical volatility

HistoricalForecast68%95%
C$1.92C$2.62C$3.32C$4.02C$4.72C$5.43TodayMar 4May 7Jul 10Aug 22Oct 5Nov 17

30-Day Vol

41.0%

Annualized

90-Day Vol

48.9%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$3.23

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$3.64C$3.16C$4.19
60 trading daysC$3.43C$2.81C$4.18
90 trading daysC$3.23C$2.53C$4.12

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Investor takeaway: Investors should take note of Aurora's strategic pivot towards international medical cannabis markets, which is driving revenue growth despite challenges in the Canadian consumer segment.

ACB's Revenue Grows 11% Year-Over-Year

Aurora Cannabis reported a net revenue of C$320.6 million for FY26, exceeding management's expectations and reflecting strong international sales.

Bull case

Aurora's recent quarterly results show impressive growth in medical cannabis revenue, which rose by 18% year-over-year. This growth highlights the success of its global strategy. Notably, 55% of its revenue now comes from outside Canada, positioning the company to take advantage of international demand.

Bear case

Despite the positive revenue growth, Aurora faces challenges in the Canadian market. A significant pricing reset and declining consumer cannabis sales could impact overall profitability in the short term. Investors should be aware of these potential hurdles.

Strong Quarterly Performance

Aurora Cannabis reported a remarkable 11% increase in net revenue for FY26, reaching C$320.6 million. This growth was primarily driven by an 18% rise in medical cannabis revenue, which now constitutes 91% of the company's total net revenue. The strategic focus on international markets has allowed Aurora to generate approximately 55% of its revenue outside Canada, indicating a successful shift towards higher-margin medical cannabis.

Challenges in the Canadian Market

While Aurora's international sales are thriving, the company is facing significant challenges in the Canadian consumer cannabis market. The decision to wind down lower-margin consumer operations is expected to impact short-term revenue. Additionally, a pricing reset due to changes in Canadian reimbursement policies could further affect profitability. Investors should remain cautious about these potential headwinds.

Future Growth Prospects

Looking ahead, Aurora Cannabis is well-positioned for long-term growth, especially with its recent acquisition of Safari Flower Company, which enhances its capabilities in the European market. The company maintains a strong financial position with substantial liquidity and no debt, allowing it to pursue further growth opportunities and navigate market fluctuations effectively.


Advertisement

Sponsored links

Advertisement